Sarcopedia

MalignantSoft tissue

Stewart-Treves Syndrome

Synonyms: Post-mastectomy angiosarcoma, lymphangiosarcoma

Pathognomonic association with chronic lymphoedema

Quick Facts

Behaviour

Malignant

Category

Soft tissue

Grade

High

Synonyms

  • Post-mastectomy angiosarcoma
  • lymphangiosarcoma

Category

Soft tissue

Behaviour

Malignant

Grade

High

Gender

Female

Tissue of Origin

Vascular

Epidemiology

  • Rare angiosarcoma arising in chronic lymphoedematous extremity
  • Classically described after radical mastectomy and lymph node dissection
  • Incidence 0.07–0.45% of post-mastectomy patients
  • Median onset 10 years post-lymphoedema onset
  • Also reported in Lower limb lymphoedema

Clinical Features

  • Violaceous or bruise-like skin nodules in oedematous extremity
  • Satellite lesions and multifocality characteristic
  • Rapid progression and ulceration
  • Painless initially, becoming painful as disease advances

Location

  • Upper extremity (arm, forearm) in post-mastectomy setting
  • Lower extremity in Lower limb lymphoedema
  • Skin and subcutaneous tissue of affected limb

Imaging

  • Multifocal skin lesions on clinical examination
  • MRI shows ill-defined enhancing subcutaneous masses
  • PET-CT for staging - often multifocal FDG-avid disease
  • Chest CT for pulmonary metastases

Pathology

  • Angiosarcoma histology - anastomosing Vascular channels lined by atypical endothelial cells
  • CD31, CD34, ERG positive
  • MYC amplification characteristic
  • Multifocal involvement of skin and subcutis

Genetics

  • MYC amplification present in 80% (distinguishes from atypical Vascular lesion)
  • KDR mutations
  • Complex karyotype

Treatment

  • Amputation often required for disease control
  • Wide local excision rarely curative due to multifocality
  • Paclitaxel-based chemotherapy
  • Radiotherapy for palliation

Prognosis

  • Very poor: median survival 19 months from diagnosis
  • 5-year survival <10%
  • Haematogenous metastasis to lungs predominant pattern
  • Early diagnosis improves outcomes marginally

Key Points

  • Pathognomonic association with chronic lymphoedema
  • MYC FISH useful to confirm diagnosis and distinguish from Benign Vascular proliferations
  • Multidisciplinary management involving oncology, plastic surgery, and lymphoedema specialists essential
  • Prevention: optimal lymphoedema management post-mastectomy

Workup - Blood Tests

FBC, U&E, LFTs - baseline and pre-chemotherapy

Workup - Local Imaging

  • MRI affected limb - ill-defined enhancing multifocal subcutaneous masses
  • CT chest/abdomen/pelvis - staging; assess for pulmonary metastases
  • PET-CT - multifocal FDG-avid disease

Workup - Biopsy

  • Core needle biopsy - confirm angiosarcoma diagnosis
  • IHC: CD31+, CD34+, ERG+
  • MYC FISH - present in 80%; distinguishes from Benign Vascular proliferation

Workup - Staging

  • CT chest/abdomen/pelvis - metastatic disease (lungs most common)
  • PET-CT - systemic staging

Workup - Other

  • MDT including oncology, Vascular surgery, lymphoedema specialist
  • Paclitaxel-based chemotherapy standard
  • Optimal lymphoedema management essential for prevention

Follow-up Summary

  1. 1

    Years 1–2

    3–4 monthly clinical review + CXR; PET-CT or CT chest at 3–4 monthly intervals (multifocal disease common)

  2. 2

    MRI of affected limb at each staging point to assess local extent

  3. 3

    Years 3–5

    6-monthly clinical review + CXR; CT chest 6-monthly

  4. 4

    Years 6–10

    Annual clinical review + CXR; CT chest annually

  5. 5

    Lymphoedema management

    ongoing specialist lymphoedema clinic referral essential

  6. 6

    Angiosarcoma specifically listed by LSESN as a histotype NOT to discharge at 10 years due to late recurrence

Medical disclaimer

The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.